• Aaron M Harris, Ademola Osinubi, Noele P Nelson, and William W Thompson.
• Division of Viral Hepatitis, CDC, 1600 Clifton Rd NE, US 12-3, Atlanta, GA 30329. Email: ieo9@cdc.gov.
• Am J Manag Care. 2020 Aug 1; 26 (8): 331-338.

ObjectivesMonitoring care and treatment for persons with chronic hepatitis B (CHB) is essential for demonstrating progress in achieving national elimination goals. We sought to evaluate insurance claims data as a source for monitoring progression along the CHB care cascade.Study DesignLongitudinal evaluation from diagnosis to treatment among commercially insured enrollees with CHB.MethodsWe used standardized procedure and diagnosis codes to identify enrollees (≥ 18 years) with CHB in large insurance claims databases to describe the CHB care cascade from 2008 to 2016. Linkage to care was defined as procedure codes for liver fibrosis assessment (alanine aminotransferase in conjunction with either hepatitis B virus DNA or hepatitis B e-antigen) more than 12 months after CHB diagnosis. Treatment was defined as a claim for any CHB prescription. We analyzed factors associated with linkage to care and treatment using unadjusted logistic regression and evaluated rates of diagnosis, linkage to care, and treatment over time.ResultsOf 16,644 individuals with CHB, 6004 (36%) were linked to care and 2926 (18%) were treated. Persons coinfected with HIV (odds ratio [OR], 0.46; 95% CI, 0.36-0.59) or hepatitis C (OR, 0.50; 95% CI, 0.34-0.73) were less likely to be linked to care, and persons coinfected with HIV (OR, 0.29; 95% CI, 0.19-0.44) were less likely to be treated. From 2009 to 2015, there was a significant decrease in CHB diagnoses but no change in the proportion linked to care and treatment.ConclusionsWe identified gaps in linkage to care and treatment in commercially insured adults with CHB.

27 keywords...

hide…